Trials / Terminated
TerminatedNCT02833714
Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis.
Characterization of Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis.
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 26 (actual)
- Sponsor
- University of North Carolina, Chapel Hill · Academic / Other
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this research is to characterize the effect of teriflunomide on the activation of B-cells, as well as its capacity to modify B-cell cytokine secretion. The in-vitro identified effects of teriflunomide on the expression of B-cell activation markers, costimulatory and antigen presenting molecules, as well as on cytokine secretion, will then be confirmed in a cohort of Relapsing Remitting Multiple Sclerosis (RRMS) patients treated with this medication.
Conditions
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2016-12-21
- Completion
- 2016-12-21
- First posted
- 2016-07-14
- Last updated
- 2017-09-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02833714. Inclusion in this directory is not an endorsement.